Please assess the completion status of the following clinical trial:

Trial Title: Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged\>= 50 and \<=85 years AND~* Moderate to severe LUTS defined as IPSS \> 11, and QoL \> 3 AND~* No improvement after an alpha blocker treatment line (Tamsulosin 0.4 mg p.d. during 1 month) AND~* Prostatic volume \>=50 ml AND~* Affiliated to a French health insurance system~Exclusion Criteria:~* Severe allergy to iodine contrast agent~* Treatment with 5-ARI on the last 6 months~* Suspected prostate cancer requiring specific management~* On-going prostatitis~* On-going urinary retention~* On-going acute urinary infection~* Acontractile detrusor~* Neurogenic lower urinary tract dysfunction~* Urethral stenosis~* Bladder diverticulum~* Bladder stone with surgical indication~* Patient refusing PAE~* Creatinine clearance \<40 ml/min~* Severe liver failure~* Contra-indication to alpha-blockers~* Hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, tamsulosin (including case of tamsulosin induced angioedema), soya, peanut or one of the excipients~* Hypersensitivity to gelatin or collagen~* Patients ineligible for pelvic angiography~* History of orthostatic hypotension~* Patient unable or unwilling to provide written informed consent~* Patient under legal protection

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Embolization (Type: EXPERIMENTAL): Prostatic Arteries Embolization
- Combined Therapy (Type: ACTIVE_COMPARATOR): Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).